Wait, we have a special
offer for you!
Click the button below to get your discount.
Get my coupon now No thanks, I'd like to pay full price
Click the button below to get your discount.
Get my coupon now No thanks, I'd like to pay full price
Only Available By Prescription
A generic drug is a copy of the brand-name drug with the same dosage, safety, strength, quality, consumption method, performance, and intended use. Before generics become available on the market, the generic company must prove it has the same active ingredients as the brand-name drug and works in the same way and in the same amount of time in the body.
The only differences between generics and their brand-name counterparts is that generics are less expensive and may look slightly different (eg. different shape or color), as trademarks laws prevent a generic from looking exactly like the brand-name drug.
Generics are less expensive because generic manufacturers don't have to invest large sums of money to develop a drug. When the brand-name patent expires, generic companies can manufacture a copy of the brand-name and sell it at a substantial discount.
Kevzara is engineered to target and block the IL-6 receptor, a key player in the inflammatory process of rheumatoid arthritis. By inhibiting this receptor, Kevzara helps to decrease the signs and symptoms of RA, including joint pain, stiffness, and swelling, and can improve physical function. It is administered through subcutaneous injection and is often considered when other treatments have failed to produce the desired results.
Before you buy Kevzara, it is crucial that you talk to your healthcare provider about potential side effects Kevzara cost.
| Fact Table | |
|---|---|
| Formula | C6388H9918N1718O1998S44 |
| License | FDA approved |
| Bioavailability | 80% |
| Legal status | Prescription Drugs |
| Chemical Name | Sarilumab |
| Elimination half-life | 21 days |
| Dosage (Strength) | 150 mg/1.14 mL and 200 mg/1.14 mL solution in a single-dose prefilled syringe |
| Pregnancy | Category C (Risk cannot be ruled out) |
| Brands | Kevzara |
| Protein binding | Not applicable (monoclonal antibody) |
| PubChem CID | 16132293 |
| MedlinePlus | a617032 |
| ChEBI | 133018 |
| ATC code | L04AC14 |
| DrugBank | DB11725 |
| KEGG | D10161 |
| Routes of administration | Subcutaneous |
Kevzara is administered as a subcutaneous injection, typically around the thighs or abdomen. The recommended dosage is based on the individual patient's condition and response to treatment, with a common starting dose being 200 mg every two weeks, potentially adjusted based on therapeutic response and tolerance. It is crucial to follow your healthcare provider's instructions carefully when using Kevzara. Before administration, allow the medication to reach room temperature, and always inspect the solution for particulate matter or discoloration.
The active ingredient in Kevzara injection is sarilumab.
Before starting Kevzara, it is essential to discuss your medical history with your healthcare provider, especially if you have:
Patients should be tested for tuberculosis before beginning treatment with Kevzara. Additionally, because Kevzara can impact the immune system, it may increase the risk of serious infections. Patients should monitor for signs of infection and report them promptly to their healthcare provider.
Kevzara can interact with other medications, vaccines, and substances, potentially altering its effectiveness or increasing side effects. Specifically, live vaccines should be avoided during treatment with Kevzara due to the increased risk of infection. Always inform your healthcare provider about all medications, supplements, and vaccines you are currently using or plan to use.
While Kevzara has been beneficial for many patients, like all medications, it can cause side effects. Common side effects include:
Serious side effects can occur and should be reported immediately to your healthcare provider. These include severe infections, allergic reactions, changes in blood cell counts, and liver enzyme elevations.
What is Kevzara used for?
Kevzara (sarilumab) is used in the treatment of adult patients with moderately to severely active rheumatoid arthritis (RA) who have had an inadequate response or intolerance to one or more biologic or non-biologic Disease-Modifying Anti-Rheumatic Drugs (DMARDs). It is typically used with methotrexate (MTX) or other traditional DMARDs.
How is Kevzara administered?
Kevzara is typically administered as a subcutaneous injection (under the skin) by a healthcare professional. The dosage and frequency depend on the individual’s condition and doctor’s recommendation.
What are the serious risks associated with Kevzara?
Serious risks include infections, including localized infections. Patients should be tested for latent tuberculosis infection before starting Kevzara. Other risks include neutropenia (decrease in neutrophil count) and reduction in platelet counts.
Can Kevzara be used as monotherapy?
Yes, Kevzara may be given as monotherapy in cases of intolerance or contraindication to methotrexate or other DMARDs.
How often should neutrophil count be monitored during Kevzara treatment?
The neutrophil count should be monitored 4 to 8 weeks after starting therapy and approximately every three months afterward.
What should be done if a patient develops a severe infection while on Kevzara?
Treatment with Kevzara should be held if a patient develops a severe or opportunistic infection. It can be reinitiated when the patient has recovered from the illness.
Is Kevzara available in generic form?
No, Kevzara is currently available only as a brand-name medication.
How does Kevzara work?
Kevzara is a monoclonal antibody that targets and inhibits interleukin-6 (IL-6), a protein involved in inflammation. By blocking IL-6, Kevzara helps reduce inflammation in rheumatoid arthritis.
What are the common side effects of Kevzara?
Common side effects may include pain, itching, skin changes at the injection site, and flu-like symptoms.
